TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MediPharm Labs ( (TSE:LABS) ) has shared an announcement.
MediPharm Labs reported a successful Q3 2025 with a 17% increase in revenue compared to Q3 2024, driven by significant gains in international medical cannabis sales, which now account for 56% of total revenue. The company also achieved a notable 19% reduction in operating expenses year-over-year, reflecting its commitment to disciplined cost management and sustainable growth, while maintaining a strong cash balance of $10.6 million.
Spark’s Take on TSE:LABS Stock
According to Spark, TipRanks’ AI Analyst, TSE:LABS is a Neutral.
The overall score reflects significant financial challenges, including profitability and cash flow issues, despite a stable balance sheet. Technical indicators suggest neutral momentum, while valuation metrics highlight ongoing losses.
To see Spark’s full report on TSE:LABS stock, click here.
More about MediPharm Labs
MediPharm Labs is a pharmaceutical company specializing in precision-based cannabinoids, focusing on international medical cannabis markets. The company offers a range of direct-to-patient, partnership, and distribution pathways to serve complex and high-value medical cannabis markets worldwide.
Average Trading Volume: 332,465
Technical Sentiment Signal: Sell
Current Market Cap: C$29.45M
See more data about LABS stock on TipRanks’ Stock Analysis page.